Your browser doesn't support javascript.
loading
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek, Fabian; Ziepert, Marita; Nickelsen, Maike; Altmann, Bettina; Glass, Bertram; Haenel, Mathias; Truemper, Lorenz; Held, Gerhard; Bentz, Martin; Borchmann, Peter; Dreyling, Martin; Viardot, Andreas; Kroschinsky, Frank P; Metzner, Bernd; Staiger, Annette M; Horn, Heike; Ott, German; Rosenwald, Andreas; Loeffler, Markus; Lenz, Georg; Schmitz, Norbert.
Afiliação
  • Frontzek F; Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
  • Ziepert M; Institute for Medical Informatics, Statistics, and Epidemiology, University Leipzig, Leipzig, Germany.
  • Nickelsen M; Onkologie Lerchenfeld, Hamburg, Germany.
  • Altmann B; Institute for Medical Informatics, Statistics, and Epidemiology, University Leipzig, Leipzig, Germany.
  • Glass B; Clinic for Haematology, Oncology, Tumour Immunology, and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany.
  • Haenel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
  • Truemper L; Haematology and Medical Oncology, Georg August University, Göttingen, Germany.
  • Held G; Department for Haematology and Oncology, Westpfalz-Klnikum Kaiserslautern, Kaiserslautern, Germany.
  • Bentz M; Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany.
  • Borchmann P; Department I of Internal Medicine, University of Cologne, Cologne, Germany.
  • Dreyling M; Department of Medicine III, Ludwig Maximilians Universität Hospital, Munich, Germany.
  • Viardot A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
  • Kroschinsky FP; Department of Medicine I, University Hospital Dresden, Dresden, Germany.
  • Metzner B; Department of Internal Medicine, Oncology, and Haematology, University Hospital Klinikum Oldenburg, Oldenburg, Germany.
  • Staiger AM; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, University of Tübingen, Stuttgart, Germany; Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany.
  • Horn H; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, University of Tübingen, Stuttgart, Germany; Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany.
  • Ott G; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, University of Tübingen, Stuttgart, Germany; Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany.
  • Rosenwald A; Institute of Pathology, University of Würzburg, Würzburg, Germany.
  • Loeffler M; Institute for Medical Informatics, Statistics, and Epidemiology, University Leipzig, Leipzig, Germany.
  • Lenz G; Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
  • Schmitz N; Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany. Electronic address: norbert.schmitz@ukmuenster.de.
Lancet Haematol ; 8(4): e267-e277, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33667420
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Transplante de Células-Tronco Hematopoéticas / Rituximab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Lancet Haematol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Transplante de Células-Tronco Hematopoéticas / Rituximab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Lancet Haematol Ano de publicação: 2021 Tipo de documento: Article